376 related articles for article (PubMed ID: 22586610)
1. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
Herman AG; Hayano M; Poyurovsky MV; Shimada K; Skouta R; Prives C; Stockwell BR
Cancer Discov; 2011 Sep; 1(4):312-25. PubMed ID: 22586610
[TBL] [Abstract][Full Text] [Related]
2. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.
Wu W; Xu C; Ling X; Fan C; Buckley BP; Chernov MV; Ellis L; Li F; Muñoz IG; Wang X
Cell Death Dis; 2015 Dec; 6(12):e2035. PubMed ID: 26720344
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
[TBL] [Abstract][Full Text] [Related]
4. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
Xu C; Fan CD; Wang X
Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081
[TBL] [Abstract][Full Text] [Related]
6. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
7. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
[TBL] [Abstract][Full Text] [Related]
8. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2.
Nie J; Xie P; Liu L; Xing G; Chang Z; Yin Y; Tian C; He F; Zhang L
J Biol Chem; 2010 Jul; 285(30):22818-30. PubMed ID: 20484049
[TBL] [Abstract][Full Text] [Related]
9. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
Wang X
Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
[TBL] [Abstract][Full Text] [Related]
10. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
11. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity.
Ranaweera RS; Yang X
J Biol Chem; 2013 Jun; 288(26):18939-46. PubMed ID: 23671280
[TBL] [Abstract][Full Text] [Related]
12. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.
Wang X; Wang J; Jiang X
J Biol Chem; 2011 Jul; 286(27):23725-34. PubMed ID: 21572037
[TBL] [Abstract][Full Text] [Related]
13. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
14. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
15. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
16. Mdm2 and MdmX partner to regulate p53.
Wang X; Jiang X
FEBS Lett; 2012 May; 586(10):1390-6. PubMed ID: 22673503
[TBL] [Abstract][Full Text] [Related]
17. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
[TBL] [Abstract][Full Text] [Related]
18. Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2.
Singh RK; Iyappan S; Scheffner M
J Biol Chem; 2007 Apr; 282(15):10901-7. PubMed ID: 17301054
[TBL] [Abstract][Full Text] [Related]
19. Critical contribution of the MDM2 acidic domain to p53 ubiquitination.
Kawai H; Wiederschain D; Yuan ZM
Mol Cell Biol; 2003 Jul; 23(14):4939-47. PubMed ID: 12832479
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
